TG Therapeutics, Inc. TGTX
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 1 Hold · 1 Sell (5 analysts)
- Avg. Price Target
- $58.80 (+20.6% upside)
Key Stats
- Today's Range
- $47.27 – $48.92
- 50-Day Range
- $40.04 – $59.30
- 52-Week Range
- $25.28 – $59.30
- Volume
- 1.07 million shs
- Average Volume
- 2.19 million shs
- Market Cap
- $7.58 billion
- P/E Ratio
- 17.72
- Dividend Yield
- —
Valuation
- P/E Ratio
- 17.72
- Price / Book
- 12.54
- Price / Sales
- 9.48
Short Interest
- Short Interest
- 11.01%
- Days to Cover
- 15.47
Financials (TTM)
- Revenue
- $799.54 million
- Net Income
- $441.49 million
- Net Margin
- 55.22%
- Return on Equity
- 73.08%
- Debt-to-Equity
- —
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Related Stocks
Compare head-to-head: TGTX vs LLY·TGTX vs JNJ·TGTX vs ABBV·TGTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.